产品
编 号：F489833
分子式：C15H20N6O6
分子量：380.36
分子式：C15H20N6O6
分子量：380.36
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 871108-05-3
产品详情
生物活性：
Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma.
体内研究：
Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation).Topical trabodenoson significantly upregulates nestin expression in the ONH of induced eyes compared with vehicle-treated no-induced eyes.Trabodenoson-treated eyes have significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. RGC counts are higher in Trabodenoson-treated eyes compared to vehicle (74% versus 47% of the contralateral eye).Animal Model:Young (3-4 months old) and aged (12 months old).
Dosage:3% or 6% in 10 μL.
Administration:Eye drop for 7 consecutive days.
Result:Decreased IOP.
Animal Model:Rats.
Dosage:3%.
Administration:Topical delivery daily.
Result:Had significantly reduced optic nerve (ON) edema.
体外研究：
Trabodenoson treatment significantly increaseS MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression.
Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma.
体内研究：
Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation).Topical trabodenoson significantly upregulates nestin expression in the ONH of induced eyes compared with vehicle-treated no-induced eyes.Trabodenoson-treated eyes have significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. RGC counts are higher in Trabodenoson-treated eyes compared to vehicle (74% versus 47% of the contralateral eye).Animal Model:Young (3-4 months old) and aged (12 months old).
Dosage:3% or 6% in 10 μL.
Administration:Eye drop for 7 consecutive days.
Result:Decreased IOP.
Animal Model:Rats.
Dosage:3%.
Administration:Topical delivery daily.
Result:Had significantly reduced optic nerve (ON) edema.
体外研究：
Trabodenoson treatment significantly increaseS MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备